Coya is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells, called Tregs. Tregs are a subset of T cells – a type of white blood cell – that function to maintain homeostasis and prevent autoimmunity.
The company is currently developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
